Showing results (91-100 of 158) with videos related to

Sort By:
Pageof 16
Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation|June 4, 2020
Use of Mycophenolate Mofetil Suspension as Part of Induction Therapy After Living-Donor Liver TransplantNoboru Harada, Tomoharu Yoshizumi, Shohei Yoshiya, et al.
Journal of Pharmacological Sciences|May 22, 2026
Establishment of spinocerebellar ataxia type 34 model mice accompanied by early glial activation and degeneration of cerebellar neuronsYuri Morikawa-Yujiri, Kensuke Motomura, Ayumu Konno, et al.
Biological & Pharmaceutical Bulletin|March 3, 2020
Increasing Diluent Volume Decreases Bendamustine-Induced Venous Irritation without Reducing the Therapeutic EfficacyShigeru Ishida, Hanae Morikawa, Hiroyuki Watanabe, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|January 27, 2023
Impact of very early introduction of everolimus on liver regeneration after partial liver transplantation in ratsMasaaki Hirata, Shintaro Yagi, Takashi Ito, et al.
International Journal of Antimicrobial Agents|September 15, 2014
Evaluation of teicoplanin concentrations and safety analysis in neonatesTakaaki Yamada, Toshio Kubota, Masako Nakamura, et al.
International Journal of Molecular Sciences|April 29, 2020
Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant RecipientsMengyu Zhang, Soichiro Tajima, Tomohiro Shigematsu, et al.
Therapeutic Drug Monitoring|September 24, 2016
Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell CarcinomaAtsuko Tanaka, Ikuko Yano, Keiko Shinsako, et al.
Clinical Pharmacology and Therapeutics|January 18, 2006
Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patientsSatohiro Masuda, Maki Goto, Sachio Fukatsu, et al.
Pageof 16